Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Compass Therapeutics, Inc.CMPX · Entity 5614 | Director | January 02, 2026 | January 05, 2026 |
| Emergent BioSolutions Inc.EBS · Entity 5902 | EVP, Chief Financial Officer | June 08, 2026 | June 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Compass Therapeutics, Inc.
Report date January 02, 2026 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.17 · Expires 2036-01-02 | Direct | 90,000 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 90,000 · Balance 90,000 F1: This grant vests in full upon the earlier of (i) June 10, 2026 or (ii) the date of the next annual meeting of the Company's stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: This grant vests in full upon the earlier of (i) June 10, 2026 or (ii) the date of the next annual meeting of the Company's stockholders.
Emergent BioSolutions Inc.
Report date June 08, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 374,083 |
Reported balance
After 2026-06-08 transaction · row 1
1 source rowRow 1 · 2026-06-08 · Tax withholding · Disposed 3,964 · Balance 374,083 F1: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CEB Inc.
Report date April 05, 2017 · Filed April 06, 2017
Section 16 reporting ended · disclosed 2017-04-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2017-04-05 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2017-04-05 · Exercise / conversion · Acquired 7,686 · Balance 45,538 F1: Represents the shares of common stock of CEB Inc. ("CEB") acquired upon vesting of the restricted stock units of CEB beneficially owned by the reporting person on the effective date of the merger ("Merger") described in the Agreement and Plan of Merger ("Merger Agreement") dated as of January 5, 2017, among Gartner, Inc. ("Gartner"), Cobra Acquisition Corp. and CEB ("Vested RSUs"). F2: Each PSU represented a right upon vesting (based on the achievement of performance goals at target performance) to receive one share of CEB's common stock. Row 2 · 2017-04-05 · Tax withholding · Disposed 1,253 · Balance 44,285 F3: Represents the number of shares of CEB common stock underlying the Vested PSUs withheld to satisfy tax withholding obligations related to the Vested PSUs. F4: The closing price on the New York Stock Exchange ("NYSE") of CEB common stock on April 3, 2017. Row 3 · 2017-04-05 · Disposition to issuer · Disposed 6,433 · Balance 37,852 F5: Represents the disposition pursuant to the Merger Agreement of the shares underlying the Vested PSUs, net of tax withholding. F6: Disposed of pursuant to the Merger Agreement in exchange for per share consideration of (a) $54.00 in cash and (b) 0.2284 of a share of common stock of Gartner. Gartner common stock had a market value of $108.70 per share based on the closing price on the NYSE on the last trading day immediately preceding the Merger (April 4, 2017). Row 4 · 2017-04-05 · Disposition to issuer · Disposed 37,852 · Balance 0 F7: Represents the number of shares of common stock of CEB beneficially owned by the reporting person immediately prior to the effectiveness of the Merger. F6: Disposed of pursuant to the Merger Agreement in exchange for per share consideration of (a) $54.00 in cash and (b) 0.2284 of a share of common stock of Gartner. Gartner common stock had a market value of $108.70 per share based on the closing price on the NYSE on the last trading day immediately preceding the Merger (April 4, 2017). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2017-04-05 | Direct | 0 |
Reported balance
After 2017-04-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-04-05 · Exercise / conversion · Disposed 23,435 · Balance 0 F8: Each restricted stock unit of CEB ("RSU") that did not vest at or before the effectiveness of the Merger was assumed by Gartner and converted into a restricted share unit payable in a number of shares of Gartner common stock, rounded up to the nearest whole share, equal to the product of (i) the applicable number of shares of CEB common stock subject to such award multiplied by (ii) the sum of (x) 0.2284 plus (y) a fraction resulting from dividing $54.00 by the closing price per share of Gartner common stock on the NYSE on the last trading day immediately preceding the closing date of the Merger ($108.70). F9: RSUs that were awarded on March 26, 2014, March 25, 2015, March 30, 2016 and March 15, 2017 and did not vest at or before the effectiveness of the Merger that rolled over into restricted share units of Gartner. F10: Pursuant to the Merger Agreement, on the effective date of the Merger, each outstanding RSU that did not vest before or in connection with the Merger rolled over into a restricted share unit of Gartner. |
| Performance Stock UnitsSEC Table II · derivative / convertible security · Expires 2017-04-05 | Direct | 0 |
Reported balance
After 2017-04-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-04-05 · Exercise / conversion · Disposed 7,686 · Balance 0 F2: Each PSU represented a right upon vesting (based on the achievement of performance goals at target performance) to receive one share of CEB's common stock. F11: Pursuant to the Merger Agreement, immediately prior to the consummation of the Merger, since certain performance goals were achieved at target performance, each outstanding PSU vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the shares of common stock of CEB Inc. ("CEB") acquired upon vesting of the restricted stock units of CEB beneficially owned by the reporting person on the effective date of the merger ("Merger") described in the Agreement and Plan of Merger ("Merger Agreement") dated as of January 5, 2017, among Gartner, Inc. ("Gartner"), Cobra Acquisition Corp. and CEB ("Vested RSUs").
F2: Each PSU represented a right upon vesting (based on the achievement of performance goals at target performance) to receive one share of CEB's common stock.
F3: Represents the number of shares of CEB common stock underlying the Vested PSUs withheld to satisfy tax withholding obligations related to the Vested PSUs.
F4: The closing price on the New York Stock Exchange ("NYSE") of CEB common stock on April 3, 2017.
F5: Represents the disposition pursuant to the Merger Agreement of the shares underlying the Vested PSUs, net of tax withholding.
F6: Disposed of pursuant to the Merger Agreement in exchange for per share consideration of (a) $54.00 in cash and (b) 0.2284 of a share of common stock of Gartner. Gartner common stock had a market value of $108.70 per share based on the closing price on the NYSE on the last trading day immediately preceding the Merger (April 4, 2017).
F7: Represents the number of shares of common stock of CEB beneficially owned by the reporting person immediately prior to the effectiveness of the Merger.
F8: Each restricted stock unit of CEB ("RSU") that did not vest at or before the effectiveness of the Merger was assumed by Gartner and converted into a restricted share unit payable in a number of shares of Gartner common stock, rounded up to the nearest whole share, equal to the product of (i) the applicable number of shares of CEB common stock subject to such award multiplied by (ii) the sum of (x) 0.2284 plus (y) a fraction resulting from dividing $54.00 by the closing price per share of Gartner common stock on the NYSE on the last trading day immediately preceding the closing date of the Merger ($108.70).
F9: RSUs that were awarded on March 26, 2014, March 25, 2015, March 30, 2016 and March 15, 2017 and did not vest at or before the effectiveness of the Merger that rolled over into restricted share units of Gartner.
F10: Pursuant to the Merger Agreement, on the effective date of the Merger, each outstanding RSU that did not vest before or in connection with the Merger rolled over into a restricted share unit of Gartner.
F11: Pursuant to the Merger Agreement, immediately prior to the consummation of the Merger, since certain performance goals were achieved at target performance, each outstanding PSU vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 08, 2026 Filed Jun 10, 2026 19:08 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 3,964 | $8.00 | $31,712.00 |
DisclosureSEC source: 0001196632-26-000017 · wk-form4_1781118501.xml · nonDerivative · entry 1 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 374,083 F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units. Read SEC document |
| April 29, 2026 Filed May 1, 2026 20:27 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 162,680 | $0.00 | $0.00 |
DisclosureSEC source: 0001196632-26-000013 · wk-form4_1777667258.xml · nonDerivative · entry 1 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 378,047 F1 · deemedExecutionDate: The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc. (the "Company"), on March 2, 2026, subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the "Amended Stock Incentive Plan"), under which the restricted stock units were granted. The Company's stockholders approved the Amended Stock Incentive Plan on April 29, 2026. F2 · shares: Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval, assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| March 05, 2026 Filed Mar 6, 2026 02:07 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 23,650 | $8.44 | $199,606.00 |
DisclosureSEC source: 0001196632-26-000009 · wk-form4_1772762821.xml · nonDerivative · entry 1 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,367 F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units Read SEC document |
| March 03, 2026 Filed Mar 6, 2026 02:07 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee Stock Option (Right to buy) · Derivative | 72,856 | $0.00 Strike: $8.99 | $0.00 |
DisclosureSEC source: 0001196632-26-000009 · wk-form4_1772762821.xml · derivative · entry 2 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 557,346 Underlying: Common Stock · 72,856 shares Expires 2033-03-02 F2 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:32 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 683 | $8.15 | $5,566.45 |
DisclosureSEC source: 0001196632-26-000006 · wk-form4_1772573548.xml · nonDerivative · entry 1 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 239,017 F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units. Read SEC document |
| February 25, 2026 Filed Mar 6, 2026 13:50 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | OtherEmployee Stock Option (Right to buy) · Derivative | 20,321 | $0.00 Strike: $61.01 | $0.00 |
DisclosureSEC source: 0001196632-26-000011 · wk-form4_1772805051.xml · derivative · entry 2 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,321 shares Expires 2026-02-25 F1 · kind: The reported stock options expired unexercised pursuant to their terms and no value was received. F3 · derivative.exercise_date: Vested in three equal installments beginning on the day prior to the first anniversary of the date of grant, subject to continued service with the company. Read SEC document |
| February 06, 2026 Filed Feb 11, 2026 00:06 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 5,642 | $10.92 | $61,610.64 |
DisclosureSEC source: 0001196632-26-000003 · wk-form4_1770768376.xml · nonDerivative · entry 2 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 239,700 F2 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units Read SEC document |
| February 06, 2026 Filed Feb 11, 2026 00:06 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Disposition to issuerCommon Stock | 46,155 | $10.92 | $504,012.60 |
DisclosureSEC source: 0001196632-26-000003 · wk-form4_1770768376.xml · nonDerivative · entry 1 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 245,342 F1 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to both cumulative revenues and adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2023 and ending December 31, 2025. On February 06, 2026, the final certification date, the Compensation Committee certified the achievement of the 2023-2025 PSUs at a payout factor of 25% of target resulting in the actual award of 15,384 shares of common stock, which is less than the 61,539 shares previously reported on March 02, 2023 and June 09, 2023. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 21:33 UTC | Compass Therapeutics, Inc. CMPX · Entity 5614 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $5.17 | $0.00 |
DisclosureSEC source: 0001171843-26-000058 · ownership.xml · derivative · entry 1 LINDAHL RICHARD S · CIK 0001196632 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2036-01-02 F1 · derivative.exercise_date: This grant vests in full upon the earlier of (i) June 10, 2026 or (ii) the date of the next annual meeting of the Company's stockholders. Read SEC document |
| October 15, 2025 Filed Oct 17, 2025 20:02 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 4,995 | $9.60 | $47,952.00 |
DisclosureSEC source: 0001196632-25-000004 · wk-form4_1760731355.xml · nonDerivative · entry 1 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 291,497 F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units. Read SEC document |
| June 08, 2025 Filed Jun 10, 2025 20:07 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 2,733 | $6.63 | $18,119.79 |
DisclosureSEC source: 0001367644-25-000138 · wk-form4_1749586014.xml · nonDerivative · entry 1 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 296,492 F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units. Read SEC document |
| May 07, 2025 Filed Mar 6, 2026 13:50 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | OtherEmployee Stock Option (Right to buy) · Derivative | 19,963 | $0.00 Strike: $48.33 | $0.00 |
DisclosureSEC source: 0001196632-26-000011 · wk-form4_1772805051.xml · derivative · entry 1 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,963 shares Expires 2025-05-07 F1 · kind: The reported stock options expired unexercised pursuant to their terms and no value was received. F2 · derivative.exercise_date: Vested in three equal installments on May 7, 2019, May 7, 2020 and May 7, 2021. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 20:18 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee Stock Options (Right to Buy) · Derivative | 178,546 | $0.00 Strike: $5.80 | $0.00 |
DisclosureSEC source: 0001367644-25-000051 · wk-form4_1741637877.xml · derivative · entry 2 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 484,490 Underlying: Common Stock · 178,546 shares Expires 2032-03-05 F2 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 20:18 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 146,888 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-25-000051 · wk-form4_1741637877.xml · nonDerivative · entry 1 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 299,225 F1 · shares: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the day prior to the anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:05 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 683 | $7.48 | $5,108.84 |
DisclosureSEC source: 0001367644-25-000030 · wk-form4_1741122292.xml · nonDerivative · entry 3 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,337 F2 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 21:05 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 1,073 | $7.48 | $8,026.04 |
DisclosureSEC source: 0001367644-25-000030 · wk-form4_1741122292.xml · nonDerivative · entry 2 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,020 F2 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units Read SEC document |
| February 12, 2025 Filed Mar 4, 2025 21:05 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Disposition to issuerCommon Stock | 16,916 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-25-000030 · wk-form4_1741122292.xml · nonDerivative · entry 1 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,093 F1 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA margin calculated on a cumulative basis over the three-year period beginning January 1, 2022 and ending December 31, 2024, as certified by the Compensation Committee following the performance period. On February 12, 2025, the final certification date, the Compensation Committee certified the achievement of the 2022-2024 PSUs at a payout factor of 0.00% of target resulting in the actual award of 0 shares of common stock, which is below the 16,916 shares previously reported on March 1, 2022. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 22:11 UTC | Compass Therapeutics, Inc. CMPX · Entity 5614 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $3.65 | $0.00 |
DisclosureSEC source: 0001171843-25-000830 · ownership.xml · derivative · entry 1 LINDAHL RICHARD S · CIK 0001196632 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-02-11 F1 · derivative.exercise_date: The options vest over 48 substantially equal monthly installments starting March 11, 2025. Read SEC document |
| October 15, 2024 Filed Oct 17, 2024 21:04 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-24-000164 · wk-form4_1729199070.xml · nonDerivative · entry 1 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 171,009 F1 · shares: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in one annual installment beginning on the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| June 08, 2024 Filed Jun 11, 2024 20:10 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 2,733 | $6.19 | $16,917.27 |
DisclosureSEC source: 0001367644-24-000105 · wk-form4_1718136614.xml · nonDerivative · entry 1 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,009 F1 · shares: Represents shares of common stock withheld to pay taxes. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 21:15 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee Stock Options (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $2.33 | $0.00 |
DisclosureSEC source: 0001367644-24-000041 · wk-form4_1710537332.xml · derivative · entry 1 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 305,944 Underlying: Common Stock · 125,000 shares Expires 2031-03-12 F1 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant. Read SEC document |
| March 01, 2024 Filed Mar 4, 2024 23:42 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 684 | $3.39 | $2,318.76 |
DisclosureSEC source: 0001367644-24-000021 · wk-form4_1709595761.xml · nonDerivative · entry 2 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,742 F1 · shares: Represents shares of common stock withheld to pay taxes. Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 23:42 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 9,037 | $3.23 | $29,189.51 |
DisclosureSEC source: 0001367644-24-000021 · wk-form4_1709595761.xml · nonDerivative · entry 1 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 159,426 F1 · shares: Represents shares of common stock withheld to pay taxes. Read SEC document |
| February 23, 2024 Filed Feb 28, 2024 01:26 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 517 | $2.74 | $1,416.58 |
DisclosureSEC source: 0001367644-24-000008 · wk-form4_1709083590.xml · nonDerivative · entry 2 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,463 F2 · shares: Represents shares of common stock withheld to pay taxes. Read SEC document |
| February 21, 2024 Filed Feb 28, 2024 01:26 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Disposition to issuerCommon Stock | 4,012 | $2.71 | $10,872.52 |
DisclosureSEC source: 0001367644-24-000008 · wk-form4_1709083590.xml · nonDerivative · entry 1 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,980 F1 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA margin calculated on a cumulative basis over the three-year period beginning January 1, 2021 and ending December 31, 2023, as certified by the Compensation Committee following the performance period. On February 21, 2024, the final certification date, the Compensation Committee certified the achievement of the 2021-2023 PSUs at a payout factor of 0.00% of target resulting in the actual award of 0 shares of common stock, which is below the 4,012 shares previously reported on February 24, 2021. Read SEC document |
| February 09, 2024 Filed Feb 14, 2024 17:03 UTC | Compass Therapeutics, Inc. CMPX · Entity 5614 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0001171843-24-000795 · ownership.xml · derivative · entry 1 LINDAHL RICHARD S · CIK 0001196632 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2034-02-08 F1 · derivative.exercise_date: The options vest over 48 substantially equal monthly installments starting March 9, 2024. Read SEC document |
| June 09, 2023 Filed Jun 14, 2023 01:21 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee Stock Option (Right to buy) · Derivative | 49,231 | $0.00 Strike: $8.39 | $0.00 |
DisclosureSEC source: 0001367644-23-000122 · wk-form4_1686705705.xml · derivative · entry 3 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,944 Underlying: Common Stock · 49,231 shares Expires 2030-06-08 F3 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant. F4 · balance_after: Represents the corrected number of securities owned due to a computational error in prior Form-4s Read SEC document |
| June 09, 2023 Filed Jun 14, 2023 01:21 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 49,231 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-23-000122 · wk-form4_1686705705.xml · nonDerivative · entry 2 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172,992 F2 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to both cumulative revenues and adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2023 and ending December 31, 2025, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%. Read SEC document |
| June 09, 2023 Filed Jun 14, 2023 01:21 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 24,616 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-23-000122 · wk-form4_1686705705.xml · nonDerivative · entry 1 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,761 F1 · shares: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company or the day prior to the annual shareholder meeting; whichever is earlier. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| April 21, 2023 Filed Apr 24, 2023 20:32 UTC | Compass Therapeutics, Inc. CMPX · Entity 5614 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.91 | $0.00 |
DisclosureSEC source: 0001171843-23-002483 · ownership.xml · derivative · entry 1 LINDAHL RICHARD S · CIK 0001196632 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-04-20 F1 · derivative.exercise_date: The options vest over 48 substantially equal monthly installments starting May 21, 2023. Read SEC document |
| March 02, 2023 Filed Mar 7, 2023 00:36 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee Stock Options (Right to Buy) · Derivative | 12,308 | $0.00 Strike: $12.06 | $0.00 |
DisclosureSEC source: 0001367644-23-000068 · wf-form4_167814936251398.xml · derivative · entry 3 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,049 Underlying: Common Stock · 12,308 shares Expires 2030-03-01 F4 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant. F2 · balance_after: Represents the corrected number of securities owned due to a computational error on prior Form-4. Read SEC document |
| March 02, 2023 Filed Mar 7, 2023 00:36 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 12,308 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-23-000068 · wf-form4_167814936251398.xml · nonDerivative · entry 2 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,145 F3 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2023 and ending December 31, 2025, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%. F2 · balance_after: Represents the corrected number of securities owned due to a computational error on prior Form-4. Read SEC document |
| March 02, 2023 Filed Mar 7, 2023 00:36 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 6,154 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-23-000068 · wf-form4_167814936251398.xml · nonDerivative · entry 1 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,837 F1 · shares: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company or the day prior to the annual shareholder meeting; whichever is earlier. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. F2 · balance_after: Represents the corrected number of securities owned due to a computational error on prior Form-4. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 19:42 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 1,074 | $12.38 | $13,296.12 |
DisclosureSEC source: 0001367644-23-000057 · wf-form4_167778614592939.xml · nonDerivative · entry 1 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,906 F1 · shares: Represents shares of common stock withheld to pay taxes. Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 01:22 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 977 | $13.71 | $13,394.67 |
DisclosureSEC source: 0001367644-23-000035 · wf-form4_167754736499121.xml · nonDerivative · entry 2 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,980 F1 · shares: Represents shares of common stock withheld to pay taxes. Read SEC document |
| February 23, 2023 Filed Feb 28, 2023 01:22 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 444 | $14.30 | $6,349.20 |
DisclosureSEC source: 0001367644-23-000035 · wf-form4_167754736499121.xml · nonDerivative · entry 1 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,957 F1 · shares: Represents shares of common stock withheld to pay taxes. Read SEC document |
| February 08, 2023 Filed Feb 11, 2023 01:35 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 2,396 | $13.25 | $31,747.00 |
DisclosureSEC source: 0001367644-23-000014 · wf-form4_167607927638617.xml · nonDerivative · entry 2 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,401 F2 · kind: Represents shares of common stock withheld to pay taxes. Read SEC document |
| February 08, 2023 Filed Feb 11, 2023 01:35 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 101 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-23-000014 · wf-form4_167607927638617.xml · nonDerivative · entry 1 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,797 F1 · kind: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted net income as a percentage of total GAAP revenue for the 2022 fiscal year, as certified by the Compensation Committee following the performance period. On February 08, 2023, the final certification date, the Compensation Committee certified the achievement of the 2020-2022 PSUs at a payout factor of 101.67% of target resulting in the actual award of 6,205 shares of common stock, which is in excess of the 6,104 shares previously reported on February 25, 2020. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 23:46 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee Stock Options (Right to Buy) · Derivative | 38,664 | $41.38 Strike: $41.38 | $1,599,916.32 |
DisclosureSEC source: 0001367644-22-000042 · wf-form4_164626472010733.xml · derivative · entry 4 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,664 Underlying: Common Stock · 38,664 shares Expires 2029-02-28 F4 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 23:46 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 16,916 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-22-000042 · wf-form4_164626472010733.xml · nonDerivative · entry 2 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,291 F2 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2022 and ending December 31, 2024, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 23:46 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 31,417 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-22-000042 · wf-form4_164626472010733.xml · nonDerivative · entry 1 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,375 F1 · shares: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest either in three equal annual installments beginning on the day prior to the first anniversary of the date of grant (9,667 shares) or on the day prior to the second anniversary date of the grant (21,750 shares), assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 23:46 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 818 | $39.64 | $32,425.52 |
DisclosureSEC source: 0001367644-22-000042 · wf-form4_164626472010733.xml · nonDerivative · entry 3 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,473 F3 · security: Represents shares of common stock withheld by the Company in exchange for payment of the employee's withholding taxes. Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 22:18 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 983 | $42.47 | $41,748.01 |
DisclosureSEC source: 0001367644-22-000032 · wf-form4_164582747302451.xml · nonDerivative · entry 2 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,958 F1 · security: Represents shares of common stock withheld by the Company in exchange for payment of the employee's withholding taxes. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 22:18 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 516 | $42.23 | $21,790.68 |
DisclosureSEC source: 0001367644-22-000032 · wf-form4_164582747302451.xml · nonDerivative · entry 1 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,941 F1 · security: Represents shares of common stock withheld by the Company in exchange for payment of the employee's withholding taxes. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 23:53 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 2,298 | $42.23 | $97,044.54 |
DisclosureSEC source: 0001367644-22-000020 · wf-form4_164574681773856.xml · nonDerivative · entry 2 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,457 F2 · security: Represents shares of common stock withheld to pay taxes. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 23:53 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 1,836 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-22-000020 · wf-form4_164574681773856.xml · nonDerivative · entry 1 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,755 F1 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted net income as a percentage of total GAAP revenue for the 2021 fiscal year, as certified by the Compensation Committee following the performance period. On February 22, 2022, the final certification date, the Compensation Committee certified the achievement of the 2019-2021 PSUs at a payout factor of 136.14% of target resulting in the actual award of 6,917 shares of common stock, which is in excess of the 5,081 shares previously reported on February 28, 2019. Read SEC document |
| November 15, 2021 Filed Nov 15, 2021 22:53 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | PurchaseCommon Stock | 3,000 | $37.46 | $112,380.00 |
DisclosureSEC source: 0001367644-21-000144 · wf-form4_163701676472498.xml · nonDerivative · entry 1 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,919 F1 · price: The price reported is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $37.32 to $37.63. Read SEC document |
| May 08, 2021 Filed May 11, 2021 20:27 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 1,054 | $61.62 | $64,947.48 |
DisclosureSEC source: 0001367644-21-000079 · wf-form4_162076485462525.xml · nonDerivative · entry 1 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,919 F1 · security: Represents shares of common stock withheld to pay taxes upon vest of restricted stock units granted under the company's stock incentive plan, as amended and restated. Read SEC document |
| February 26, 2021 Filed Feb 26, 2021 22:12 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 819 | $97.15 | $79,565.85 |
DisclosureSEC source: 0001367644-21-000041 · wf-form4_161437750812785.xml · nonDerivative · entry 4 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,973 F3 · security: Represents shares of common stock withheld to pay taxes. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 22:12 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee Stock Options (Right to Buy) · Derivative | 16,043 | $93.49 Strike: $93.49 | $1,499,860.07 |
DisclosureSEC source: 0001367644-21-000041 · wf-form4_161437750812785.xml · derivative · entry 5 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,043 Underlying: Common Stock · 16,043 shares Expires 2028-02-23 F4 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.